| General Information | |
|---|---|
| ZINC ID | ZINC000033999554 |
| Molecular Weight (Da) | 456 |
| SMILES | C[C@@H](NC(=O)C(C)(C)Oc1ccc(Cl)cc1)[C@H](Cc1ccc(Cl)cc1)c1ccccc1 |
| Molecular Formula | C26Cl2N1O2 |
| Action | Inverse Agonist |
| Physicochemical Details | |
|---|---|
| Molar Refractivity | 127.093 |
| HBA | 2 |
| HBD | 1 |
| Rotatable Bonds | 8 |
| Heavy Atoms | 31 |
| LogP | 7.088 |
| Activity (Ki) in nM | 616.595 |
| Polar Surface Area (PSA) | 38.33 |
| Pharmacokinetic Properties (AdmetSAR) | |
|---|---|
| Human intestinal absorption | + |
| Caco-2 | - |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | + |
| P-glycoprotein substrate | - |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | - |
| Cyp2d6 substrate | - |
| Cyp3a4 inhibition | - |
| Cyp2c9 inhibition | + |
| Cyp2c19 inhibition | + |
| Cyp2d6 inhibition | - |
| Cyp1a2 inhibition | + |
| Acute oral toxicity | + |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | - |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | - |
| Glucocorticoid receptor binding | + |
| Thyroid receptor binding | + |
| Androgen receptor binding | + |
| Plasma protein binding | 1.136 |
| Pharmacokinetic Properties (SwissADME) | |
|---|---|
| Number of aromatic heavy atoms | 18 |
| Fraction csp3 | 0.27 |
| Ilogp | 4.16 |
| Xlogp3 | 7.22 |
| Wlogp | 6.68 |
| Mlogp | 5.56 |
| Silicos-it log p | 6.96 |
| Consensus log p | 6.12 |
| Esol log s | -7.05 |
| Esol solubility (mg/ml) | 0.0000403 |
| Esol solubility (mol/l) | 8.83E-08 |
| Esol class | Poorly sol |
| Ali log s | -7.85 |
| Ali solubility (mg/ml) | 0.00000647 |
| Ali solubility (mol/l) | 1.42E-08 |
| Ali class | Poorly sol |
| Silicos-it logsw | -9.98 |
| Silicos-it solubility (mg/ml) | 4.74E-08 |
| Silicos-it solubility (mol/l) | 1.04E-10 |
| Silicos-it class | Poorly soluble |
| Pgp substrate | |
| Log kp (cm/s) | -3.96 |
| Lipinski number of violations | 1 |
| Ghose number of violations | 1 |
| Veber number of violations | 0 |
| Egan number of violations | 1 |
| Muegge number of violations | 1 |
| Bioavailability score | 0.55 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 0 |
| Leadlikeness number of violations | 3 |
| Synthetic accessibility | 3.51 |
| Pharmacokinetic Properties (ADMETLab) | |
|---|---|
| Logs | -6.854 |
| Logd | 4.986 |
| Logp | 6.884 |
| F (20%) | 0.01 |
| F (30%) | 0.038 |
| Mdck | 6.83E-06 |
| Ppb | 1.004 |
| Vdss | 0.884 |
| Fu | 0.0122 |
| Cyp1a2-inh | 0.288 |
| Cyp1a2-sub | 0.828 |
| Cyp2c19-inh | 0.88 |
| Cyp2c19-sub | 0.161 |
| Cl | 3.216 |
| T12 | 0.034 |
| H-ht | 0.883 |
| Dili | 0.941 |
| Roa | 0.052 |
| Fdamdd | 0.468 |
| Skinsen | 0.023 |
| Ec | 0.003 |
| Ei | 0.008 |
| Respiratory | 0.054 |
| Bcf | 2.841 |
| Igc50 | 4.676 |
| Lc50 | 6.129 |
| Lc50dm | 6.087 |
| Nr-ar | 0.35 |
| Nr-ar-lbd | 0.016 |
| Nr-ahr | 0.009 |
| Nr-aromatase | 0.036 |
| Nr-er | 0.438 |
| Nr-er-lbd | 0.018 |
| Nr-ppar-gamma | 0.005 |
| Sr-are | 0.135 |
| Sr-atad5 | 0.005 |
| Sr-hse | 0.012 |
| Sr-mmp | 0.65 |
| Sr-p53 | 0.112 |
| Vol | 465.217 |
| Dense | 0.978 |
| Flex | 0.474 |
| Nstereo | 2 |
| Nongenotoxic carcinogenicity | 1 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 0 |
| Surechembl | 0 |
| Nonbiodegradable | 2 |
| Skin sensitization | 0 |
| Acute aquatic toxicity | 1 |
| Toxicophores | 0 |
| Qed | 0.411 |
| Synth | 2.895 |
| Fsp3 | 0.269 |
| Mce-18 | 40 |
| Natural product-likeness | -0.535 |
| Alarm nmr | 1 |
| Bms | 0 |
| Chelating | 0 |
| Pfizer | 1 |
| Gsk | Rejected |
| Goldentriangle | Accepted |